Treatment of LGI1 Encephalitis
Start high-dose corticosteroids immediately once infection is ruled out, as LGI1 encephalitis is particularly steroid-responsive, and early treatment is critical to prevent long-term cognitive impairment. 1
First-Line Acute Immunotherapy
Initial Treatment Selection
Corticosteroids are the preferred first-line agent for LGI1 encephalitis based on guideline recommendations specifically identifying this condition as steroid-responsive 1. Evidence from a 2022 Mayo Clinic study of 118 patients demonstrated that corticosteroids were significantly more effective than IVIG alone, achieving:
- 61% resolution of faciobrachial dystonic seizures (vs 7% with IVIG, p=0.002)
- Greater improvement in modified Rankin Scale scores (ΔmRS 2 vs 0, p=0.008)
- Better cognitive outcomes (ΔKokmen STMS 5 points vs 0, p=0.01) 2
Treatment protocol:
- High-dose intravenous methylprednisolone (typically 1g daily for 3-5 days)
- Followed by oral prednisone taper over ≥3 months 3
- Alternative first-line options if steroids contraindicated: IVIG or plasma exchange 1
When to Escalate or Combine Therapy
If no clinical, radiological, or electrophysiological improvement occurs by the end of the initial treatment cycle:
- Add IVIG or plasma exchange to corticosteroids 1
- Consider IVIG first in agitated patients or those with bleeding disorders
- Consider plasma exchange first if severe hyponatremia, high thromboembolic risk, or associated demyelination 1
Important caveat: Many patients have ongoing subclinical symptoms even after apparent initial improvement. A 2024 Spanish prospective study found that 79% of patients had disrupted sleep structure and 63% had ongoing clinical features at median 88 days post-immunotherapy that were initially unrecognized but responded to additional treatment 4.
Second-Line Immunotherapy
Indications for Second-Line Agents
If no meaningful clinical or radiological response occurs 2-4 weeks after completion of combined first-line therapy, initiate second-line agents 1.
Rituximab is the preferred second-line agent for LGI1 encephalitis as this is antibody-mediated autoimmunity 1. Key evidence:
- A 2024 prospective study found that absence of rituximab use before initial follow-up was associated with persistent cognitive deficits (OR 4.0,95% CI 1.5-10.7, p=0.0015) 4
- A 2021 Mayo Clinic study showed that long-term steroid-sparing immunotherapy (including rituximab) reduced relapse risk (HR 0.28,95% CI 0.11-0.73, p=0.009) 5
Maintenance Immunotherapy
The evidence regarding maintenance therapy is mixed but favors long-term immunosuppression in most cases:
Arguments for maintenance therapy:
- Relapses occur in 33-41% of patients 3, 5
- A 2024 study showed mycophenolate mofetil significantly reduced relapse risk (HR 0.463, p=0.030) 6
- Long-term steroid-sparing agents associated with lower relapse rates 5
Arguments for prolonged corticosteroids without maintenance:
- A 2023 Canadian study using prolonged corticosteroids (median 6.3 months) without steroid-sparing maintenance showed 89% favorable outcomes with only 33% relapse rate 3
- However, relapses were more common in refractory disease cases 3
Recommended approach:
- Start bridging therapy with gradual oral prednisone taper (≥3 months) 1, 3
- Consider rituximab or mycophenolate mofetil for maintenance in patients with:
Critical Pitfalls to Avoid
Don't wait for antibody results to start treatment - begin immunotherapy once infection is excluded 7
Don't assume good functional recovery means complete resolution - 65% of patients have persistent cognitive deficits at 12 months despite good mRS scores 4, and 37% have short-term memory impairments at long-term follow-up 2
Don't miss faciobrachial dystonic seizures - these were unnoticed in 17% of patients but are highly steroid-responsive 4
Don't undertreat early - cognitive deficits are linked to immunotherapy-resistant white matter network changes 8, suggesting a window for preventing permanent damage
Screen for malignancy - perform CT chest/abdomen/pelvis as LGI1 can be paraneoplastic 1